HIV/AIDS Clinical Trial
Official title:
A Mobile Health Application for Engagement in Care Among Youth Living With HIV
Verified date | June 2022 |
Source | University of California, San Francisco |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In the US, fewer than 6% of all youth living with HIV (YLWH) achieve HIV viral suppression. However, health disparities among youth extend across the entire HIV care continuum in that there is a strong association between younger age and later HIV diagnosis, lower engagement in care, lower levels of antiretroviral therapy (ART) adherence, and worse HIV clinical outcomes. In response to this critical public health dilemma, the investigators propose to develop a novel mobile health application ("app") to improve engagement in health care and ART adherence and to pilot test this mobile health app in 18-29-year-old YLWH residing in San Francisco. The aims of this study are to: Aim 1: Build on a theory-guided model and formative work to complete the development of a novel personalized mobile health app for improved HIV clinical outcomes among YLWH (includes field test of initial release to ensure adequate usability and engagement). Aim 2: Conduct a six-month single arm pilot study to examine WYZ feasibility and acceptability among YLWH ( N = 76) living in the San Francisco Bay Area. Finally, the investigators will conduct in-depth qualitative interviews with a subset of participants (N = 20) and clinical team members (N = 10) whose patients participated in the pilot study. The investigators hypothesize that this mobile health app will be feasible and acceptable and will result in improved HIV clinical outcomes. Upon completion, the investigators will be ready to test the efficacy of this app in a subsequent large-scale randomized control trial among a population that is disproportionately impacted by HIV and at elevated risk for poor clinical outcomes.
Status | Completed |
Enrollment | 83 |
Est. completion date | May 1, 2020 |
Est. primary completion date | May 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 29 Years |
Eligibility | Eligibility Criteria: - Must be between 18 and 29 years of age - Must be living with HIV - Must reside and/or get care in San Francisco Bay Area - Must be able to provide informed consent to be a research participant - Must be able to speak and understand English - Must have access to an Android (5.0 or higher) or iOS (10.0 or higher) mobile phone Exclusion Criteria: Evidence of cognitive impairment or psychotic disorder that prevents one from understanding the purpose of the study and/or participating fully in study activities. This determination will be made by trained study staff in consultation with the principal investigator. |
Country | Name | City | State |
---|---|---|---|
United States | University of California San Francisco, Mission Bay Campus | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco | National Institute of Mental Health (NIMH) |
United States,
Erguera XA, Johnson MO, Neilands TB, Ruel T, Berrean B, Thomas S, Saberi P. WYZ: a pilot study protocol for designing and developing a mobile health application for engagement in HIV care and medication adherence in youth and young adults living with HIV. BMJ Open. 2019 May 5;9(5):e030473. doi: 10.1136/bmjopen-2019-030473. — View Citation
Lisha NE, Neilands TB, Erguera XA, Saberi P. Development of the Mobile Technology Vulnerability Scale among Youth and Young Adults Living with HIV. Int J Environ Res Public Health. 2021 Apr 15;18(8). pii: 4170. doi: 10.3390/ijerph18084170. — View Citation
Saberi P, Lisha NE, Erguera XA, Hudes ES, Johnson MO, Ruel T, Neilands TB. A Mobile Health App (WYZ) for Engagement in Care and Antiretroviral Therapy Adherence Among Youth and Young Adults Living With HIV: Single-Arm Pilot Intervention Study. JMIR Form R — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Mobile Application Engagement Index (EI) | The engagement index (EI) measures overall engagement with the app. The score is calculated by adding scores for 5 sub-indices: (1) click depth (number of pages viewed per session), (2) loyalty (frequency of application access), (3) recency (time between each session), (4) interaction (number of notifications opened), (5) feedback (participant's satisfaction with the application).
The final score incorporated click depth, loyalty, recency, interaction, and feedback sub-indices. Equal weight was assigned for each of the sub-index. Four of the sub-indices were calculated using app data. The feedback index was informed using responses to the 6-month satisfaction survey. The EI was then converted to a value between 0 and 100. Cut-off points were developed based on the distribution of the total samples' EI scores using quartiles. Participants were then categorized as either poorly, moderately, or highly engaged. |
Baseline To 6 Months | |
Primary | Feasibility: Rate of Participant Recruitment | Recruit at least 55 participants (i.e. 70% of target N) | 8 Months | |
Primary | Feasibility: Frequency of WYZ Access | Percentage of participants who achieve an average of 1 log-in per week | Baseline to 6 Months | |
Primary | Feasibility: Length of Session (Minutes) | Percentage of participants who achieve an average of 15 minutes in application per week | Baseline To 6 Months | |
Primary | Feasibility: Rate of Use of Refill Reminders | Percentage of participants that use feature once monthly (if receiving 30-day ART supply) | Baseline To 6 Months | |
Primary | Feasibility: Rate of Use of ART Adherence Tracking | Percentage of participants that track med adherence at least 3 times per week | Baseline To 6 Months | |
Primary | Feasibility: Rate of Access of Laboratory Data | Percentage of participants that review laboratory data at least one-time per month | Baseline To 6 Months | |
Primary | Feasibility: Rate of Communication With Clinical Team Members | Percentage of participants who achieve an average of 1 communication exchange per month with clinical team member | Baseline To 6 Months | |
Primary | Feasibility: Rate of Communication With Peers | Percentage of participants who achieve an average of one post or response to a post per week | Baseline To 6 Months | |
Primary | Feasibility: Rate of Access of Health News | Percentage of participants who review health news at least once per week | Baseline To 6 Months | |
Primary | Feasibility: Rate of Access of Event Calendar | Percentage of participants who review event calendar at least once per week | Baseline To 6 Months | |
Primary | Feasibility: Time For Participant Onboarding (Minutes) | Average time to onboard new participant (including downloading app and reviewing app features) | Baseline To 6 Months | |
Primary | Feasibility: Time To Maintain & Support (Minutes) | Average time required for administrative, maintenance, and support per participant per week (excludes 1st visit) | Baseline To 6 Months | |
Secondary | Acceptability: Participant Retention | Percentage of individuals who enrolled and completed the study at 6 months | Baseline To 6 Months | |
Secondary | Acceptability: System Usability Score | Ten-items, Likert scale (1-5), 1 is strongly disagree and 5 is strongly agree
To calculate the System Usability Score (SUS), first sum the score contributions from each item. Each item's score contribution will range from 0 to 4. For items 1,3,5,7,and 9 the score contribution is the scale position minus 1. For items 2,4,6,8 and 10, the contribution is 5 minus the scale position. Multiply the sum of the scores by 2.5 to obtain the overall value of System Usability (SU). SUS scores have a range of 0 to 100. |
Baseline To 6 Months | |
Secondary | Acceptability: Satisfaction Acceptability Questionnaire | Measure participant satisfaction with intervention delivered via mobile application at 6-months using a 30-item questionnaire (1 Excellent-6 Unsatisfied) administered through an online survey. An average score greater than or equal to 144 (80%) will be considered acceptable. | Baseline To 6 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03215901 -
Life Plans Intervention Study
|
N/A | |
Completed |
NCT03289676 -
Storytelling Narrative Communication Intervention for Smoking Cessation in Women Living With HIV
|
Phase 1 | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Active, not recruiting |
NCT04064567 -
Linking High-Risk Jail Detainees to HIV Pre-Exposure Prophylaxis: PrEP-LINK
|
N/A | |
Completed |
NCT04013295 -
Prize-linked Savings Initiatives for Promoting Better Health and Economic Outcomes in Kenya
|
N/A | |
Recruiting |
NCT04405700 -
Measuring Adverse Pregnancy and Newborn Congenital Outcomes
|
||
Recruiting |
NCT03984136 -
HIV Results Exchange Mechanism on Promoting HIV Testing Among MSM
|
N/A | |
Completed |
NCT02928900 -
Patient Actor Training to Improve HIV Services for Adolescents in Kenya
|
N/A | |
Recruiting |
NCT03268109 -
COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old
|
||
Completed |
NCT02797262 -
Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System
|
N/A | |
Completed |
NCT02376582 -
Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS
|
Phase 1 | |
Completed |
NCT01957865 -
Real-Time Antiretroviral Therapy Adherence Intervention in Uganda
|
N/A | |
Terminated |
NCT01443923 -
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
|
Phase 4 | |
Completed |
NCT01616940 -
Minority AIDS Initiative Retention and Re-Engagement Project
|
N/A | |
Completed |
NCT01910714 -
Adapting and Evaluating an EBI to Prevent HIV/AIDS Risk Among Apache Youth
|
N/A | |
Completed |
NCT01084421 -
A Computer-Based Parent/Adolescent HIV Communication Intervention for Latinos
|
N/A | |
Completed |
NCT01596322 -
International HIV Antiretroviral Adherence, Resistance and Survival
|
N/A | |
Completed |
NCT03643705 -
A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention
|
N/A | |
Completed |
NCT03923231 -
Pharmacokinetics of Atazanavir in Special Populations
|